8-K: TuHURA Biosciences Completes Acquisition of Kineta, Expanding Immuno-Oncology Pipeline with Phase 2 Ready Asset

TuHURA Biosciences, Inc. has successfully completed its acquisition of Kineta, Inc., integrating Kineta's novel VISTA inhibiting antibody, TBS-2025, into its late-stage immuno-oncology pipeline and unlocking a $12.5 million aggregate PIPE financing tranche.

Summary

• TuHURA Biosciences, Inc. completed the acquisition of Kineta, Inc. on June 30, 2025, through a two-step merger process.
• Each share of Kineta common stock was converted into the right to receive 0.185298 shares of TuHURA common stock, totaling an aggregate of 2,868,168 shares of TuHURA common stock issued at closing.
• Kineta stockholders are also entitled to a pro rata portion of an additional 1,129,884 shares of TuHURA common stock to be issued after six months, subject to adjustment for losses.
• Former Kineta stockholders will receive cash consideration for any fractional shares of TuHURA common stock at a rate of $5.7528 per fractional share.
• In-the-Money Company Stock Options were exercised for merger consideration, while Out-of-the-Money options were canceled for no consideration.
• As a result of the merger, Kineta, Inc. ceased to exist, and Merger Sub II, a wholly-owned subsidiary of TuHURA, continued as the surviving entity, renamed Kineta, LLC.
• Kineta Common Stock has been delisted from the OTC Pink Market, and trading was halted; the company intends to file Form 15 to terminate SEC registration and suspend reporting obligations.
• The acquisition adds TBS-2025 (formerly KVA1213), a Phase 2 ready novel VISTA inhibiting monoclonal antibody, to TuHURA's immuno-oncology pipeline.
• Completion of the acquisition unlocked the fourth tranche of funds from a previously announced $12.5 million aggregate PIPE financing.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the successful completion of a strategic acquisition that significantly expands the company's pipeline with a Phase 2 ready asset, addresses a critical resistance mechanism in cancer immunotherapy, and unlocks a substantial financing tranche. The delisting of Kineta stock is a procedural consequence of the merger, not a negative for the combined entity's outlook.

Positives

• Acquisition of TBS-2025 (formerly KVA1213) expands TuHURA's immuno-oncology pipeline with a Phase 2 ready drug candidate.
• TBS-2025 has the potential to overcome acquired resistance to cancer immunotherapy, complementing TuHURA's existing focus on primary resistance.
• The acquisition provides synergies for TuHURA's therapeutic focus and antibody drug conjugate (ADC) technology, with potential for TBS-2025 to be conjugated to a Delta Opioid Receptor inhibitor.
• TuHURA plans to initiate a relatively inexpensive, small Phase 2 study for TBS-2025 in NPM1 mutated AML, aiming to augment response rates and decrease relapse.
• The completion of the acquisition unlocked the fourth tranche of funds from a $12.5 million aggregate PIPE financing, strengthening TuHURA's financial position.

Negatives

• Kineta Common Stock is no longer listed on the OTC Markets Group platform, and trading was halted, impacting former Kineta shareholders' liquidity.
• Kineta, Inc. ceased to exist as a separate entity, becoming Kineta, LLC, a wholly-owned subsidiary of TuHURA.

Risks

• Forward-looking statements are subject to risks and uncertainties, and actual results or developments may differ materially from those set forth in these statements.
• The timing of future development programs, studies, and trials for TBS-2025 is subject to various factors and may not proceed as anticipated.
• The effectiveness of TBS-2025 in clinical trials, particularly in combination therapies, is not guaranteed and may not yield expected results.
• The issuance of additional TuHURA Common Stock after six months is subject to adjustment for losses incurred or accrued during that period, potentially reducing the number of shares received by former Kineta stockholders.

Future Outlook

TuHURA Biosciences plans to initiate a Phase 2 randomized trial for TBS-2025 (formerly KVA1213), its newly acquired VISTA inhibiting antibody, in the second half of 2025. This trial will investigate TBS-2025 in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML. TuHURA also continues to advance its lead innate immune agonist, IFx-2.0, in a Phase 3 registration trial for advanced or metastatic Merkel Cell Carcinoma.

Management Comments

• James Bianco, M.D., President and Chief Executive Officer of TuHURA, stated that the acquisition of VISTA expands TuHURA's pipeline with a Phase 2 ready drug candidate, TBS-2025, which has the potential to overcome acquired resistance to cancer immunotherapy.
• Dr. Bianco also highlighted the synergies across TuHURA's therapeutic focus and antibody drug conjugate (ADC) technology, noting the investigation into conjugating TBS-2025 to a Delta Opioid Receptor inhibitor(s) for targeting myeloid derived suppressor cells.
• Dr. Bianco expressed belief that a relatively inexpensive, small Phase 2 study can determine if TBS-2025 can augment response rates and decrease relapse in patients with NPM1 mutated relapsed or refractory AML.

Industry Context

The acquisition positions TuHURA Biosciences more strongly in the immuno-oncology space by adding a novel VISTA inhibiting antibody, TBS-2025, to its pipeline. This move addresses a critical challenge in cancer treatment: overcoming acquired resistance to existing immunotherapies. By targeting VISTA, which is highly expressed on myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, TuHURA aims to enhance immune recognition and attack, particularly in difficult-to-treat cancers like NPM1 mutated AML. This strategy aligns with broader industry trends focusing on combination therapies and novel immune checkpoint targets beyond PD-1/PD-L1 to improve patient outcomes.

Comparison to Industry Standards

• TuHURA's lead candidate, IFx-2.0, is being investigated in a Phase 3 randomized placebo-controlled trial as an adjunctive therapy to Keytruda (pembrolizumab) for first-line treatment of advanced or metastatic Merkel Cell Carcinoma, a standard approach for enhancing checkpoint inhibitor efficacy.
• TBS-2025's planned Phase 2 trial in NPM1 mutated AML in combination with a menin inhibitor directly targets a specific genetic mutation and a known mechanism of immune escape (VISTA expression on leukemic blasts), aiming to improve upon current standard of care (menin inhibitors alone) in a high-relapse setting.
• The focus on VISTA inhibition, a checkpoint distinct from those mostly present on activated T cells, represents a strategic diversification within the immuno-oncology landscape, as VISTA is predominately expressed on myeloid cells, including MDSCs, which are key drivers of immunosuppression in the tumor microenvironment.
• The exploration of TBS-2025 as a bi-functional, bi-specific antibody drug conjugate (ADC) with a Delta Opioid Receptor inhibitor reflects an innovative approach to targeting MDSCs, aligning with the industry's growing interest in ADCs for precise drug delivery and enhanced therapeutic effect.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders (Former Kineta):** Their shares were converted into TuHURA common stock, and Kineta stock was delisted, impacting their direct ownership and liquidity in Kineta. They will receive additional TuHURA shares and potential cash consideration at later dates.
• **Shareholders (TuHURA):** The acquisition expands TuHURA's pipeline with a promising Phase 2 asset, potentially enhancing long-term value and strategic positioning in the immuno-oncology market. The unlocking of PIPE financing strengthens the company's capital base.
• **Employees (Former Kineta):** While not explicitly detailed, the merger implies integration into TuHURA's operational structure, potentially affecting roles and reporting lines.
• **Customers/Patients:** The acquisition of TBS-2025 could lead to new therapeutic options for patients with cancers like NPM1 mutated AML, potentially improving treatment outcomes by addressing acquired resistance.
• **Regulatory Authorities:** The company will file Form 15 to terminate SEC registration and suspend reporting obligations for Kineta, Inc., streamlining regulatory compliance for the combined entity.

Next Steps

• TuHURA Biosciences plans to initiate a Phase 2 randomized trial for TBS-2025 in the second half of 2025.
• Kineta, LLC intends to file a certification on Form 15 with the SEC to terminate the registration of its common stock under Section 12(g) of the Exchange Act.
• Kineta, LLC will suspend its reporting obligations under Sections 13 and 15(d) of the Exchange Act.
• Issuance of additional TuHURA Common Stock to former Kineta stockholders is expected after six months following the closing of the Mergers, subject to adjustment.
• Potential cash consideration payments related to disposed legacy Kineta assets will be made at a later date.

Key Dates

Keywords

Biotech, Immuno-oncology, Acquisition, Merger, VISTA inhibitor, Cancer immunotherapy, Clinical trials, AML, Merkel Cell Carcinoma, Oncology, Pharmaceuticals, Drug development, Antibody drug conjugate, PIPE financing